Business
Lipocine Announces Presentations at The International Liver Congress™ 2021 Digital Event
SALT LAKE CITY, June 23, 2021 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine
About this update from Lipocine Inc.
[{"type":"text","content":"SALT LAKE CITY, June 23, 2021 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that clinical data will be presented at The International Liver Congress™ 2021, the annual meeting of the European Association for the Study of the Liver (\"EASL\"), Digital Event, on June 23-26, 2021. \n\n \n \n \n \n \n \n\n \n1. Title: Oral LPCN 1144 treatment significantly reduced liver fat and key liver injury markers in biopsy confirmed NASH subjects: Results of a Phase 2 randomized controlled study Low Testosterone in Males may Warrant Liver Health Assessment Intervention Session Type: Poster Session Category: NAFLD: Therapy Date: June 23, 2021 8:00 a.m. E.T. to 6:00 p.m. C.E.T ePoster Session: June 25, 2021 11:30 a.m. C.E.T. 2. Title: High prevalence of low normal or overtly hypogonadal levels of testosterone observed in histologically established NASH subjects in LiFT Study Session Type: Poster Session Category: NAFLD: Therapy Date: June 23, 2021 8:00 a.m. E.T. to 6:00 p.m. C.E.T 3. Title: LPCN 1144 improves body composition in biopsy-confirmed NASH patients Session Type: Poster Session Category: Late Breaker: General Hepatology Date: June 23, 2021 8:00 a.m. E.T. to 6:00 p.m. C.E.T \nAbout LipocineLipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148, LPCN 1154 and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, has received tentative approval from the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. LPCN 1144, an oral prodrug of bioidentical testosterone, recently completed a proof-of-concept clinical study demonstrating the potential utility in the treatment of non-cirrhotic NASH. LPCN 1144 is currently being studied in a Phase 2 clinical study. TLANDO XR, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing. In a phase 2 clinical evaluation when administered as once daily or twice daily TLANDO XR met the typical primary and ...